aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs’ rights firm Hagens Berman has been investigating the alleged claims. The firm urges investors in aTyr who suffered significant losses to submit your losses now. ...